|
Synthorx, Inc.
Ticker Symbol: THOR* CUSIP: 87167A103 Exchange: NGS
* NOTE: This security is no longer trading as of 1/23/20
Company's Online Profile
BUSINESS: Synthorx, Inc. is a biopharmaceutical company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. The Company's proprietary, first-of-its-kind platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics called Synthorins.
|
Notes: January 23, 2020 -- On December 23, 2019, Thunder Acquisition Corp (purchaser) commenced a tender offer to acquire all of the outstanding shares of common stock of Synthorx, Inc. (Company), $0.001 par value per share, at a purchase price of $68.00 per Share in cash, without interest thereon and net of any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 23, 2019. On January 23, 2020, Sanofi (Parent) announced that the offering period of the Offer had expired at one minute past 11:59 p.m., Eastern Time, on January 22, 2020 (the “Expiration Time”) and that as of such time, based on the information provided by the depositary for the Offer, 27,443,994 Shares (not including 1,135,448 Shares tendered by notice of guaranteed delivery for which Shares have not yet been delivered in satisfaction of such guarantee) were validly tendered and not validly withdrawn pursuant to the Offer prior to the Expiration Time, representing approximately 83.7% of the outstanding Shares. Following the completion of the Offer, on January 23, 2020, pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”), Purchaser merged with and into the Company (the “Merger”), with the Company continuing as the surviving corporation (the “Surviving Corporation”) and an indirect wholly owned subsidiary of Parent.
|
IPO - 12/7/2018 - 13.69 Million Shares @ $11.00/share.
Link to IPO Prospectus
Small Cap Stock -
Market Value $ 170 Million
Yahoo News Summary for THOR*
YAHOO! Profile for THOR*
Yahoo Detailed Quote
MarketWatch Quote
MSN Company Report for THOR*
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Address and Phone Numbers |
| Address: 11099 N. Torrey Pines Road, Suite 190, La Jolla, CA 92037 |
| Main Phone Number |
858-750-4700 |
| Fax Number |
Not Available |
| Investor Relations
|
858-750-4715
|
| CEO - Laura Shawver |
CFO - Tighe Reardon |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
